

Ref. No: 090130521
From: Commercial
Date: 13/05/21
Subject: Usage of anti-VEFG treatments for eye conditions

REQUEST

1. For the 4-month period from January to April 2021, how many patients has your trust treated with the following anti-VEGF treatments:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

3. Within your trust, how many **intra-vitreous injections/implants** of each the following treatments have been used (for any eye condition) in the four-month period from January to April 2021:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone
- Ranibizumab

4. If your trust is able to identify **intra-vitreous injections/implants** by eye condition, please provide the number of injections/implants used in the four-month period from January to April 2021 for each of the following conditions: Diabetic Macular Oedema (DMO)

- Aflibercept

- Bevacizumab
- Dexamethasone
- Ranibizumab

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

RESPONSE

Under section 12 of the Freedom of Information Act St Helens & Knowsley Teaching Hospitals Trust does not have to comply with a request if we estimate that the cost of complying with your request would exceed the appropriate limit of £450. The appropriate limit has been specified in regulations. This represents the estimated cost of one person spending 2½ working days in answering the remainder of your questions. Under section 12 of the Freedom of Information Act the Department is not obliged to comply with your request and we will not be processing your request further.